Overview

Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the effectiveness of the antipsychotic medication olanzapine in treating outpatients with anorexia nervosa.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Olanzapine
Criteria
Inclusion Criteria:

- Meets DSM-IV criteria (not including amenorrhea) for AN

- Body mass index (BMI) less than 19 kg/m2 and greater than 14 kg/m2

- Patient (or family if the patient is a minor) refuses hospitalization

- Free of psychotropic medication (4 weeks medication free for fluoxetine and
antipsychotic medication; 2 weeks medication free for all others) OR on a stable dose
of an SSRI or SNRI (venlafaxine) for 4 weeks before study entry

- Prior treatment of AN

Exclusion Criteria:

- Any medical or psychiatric problem requiring urgent attention and/or any significant
comorbid illness not likely to benefit from proposed treatments

- Allergy to olanzapine

- Significant orthostatic high blood pressure

- Recent commencement of psychotherapy in the community

- Diabetes mellitus, with a fasting serum glucose greater than 120 mg/dL or nonfasting
serum glucose greater than 140 mg/dL

- Known history of current or past jaundice

- Known history of narrow angle glaucoma

- Active substance abuse or dependence

- Schizophrenia, schizophreniform disorder, or bipolar illness

- Movement disorder or presence of tics

- History of tardive dyskinesia

- History of seizures

- Pregnant